Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Angiotensin (1-7)

Cardiovascular & Anti-inflammatory

Molecular Dossier

  • Rank Index: 65
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: MW: 899.0 Da | Sequence: Asp-Arg-Val-Tyr-Ile-His-Pro | ACE2 cleavage product of Ang II

About Angiotensin (1-7)

Heptapeptide endogenous to the renin-angiotensin system (RAS) that acts as a counter-regulatory axis to Angiotensin II. Activates the MAS receptor to produce vasodilation, anti-inflammatory, anti-fibrotic, and cardioprotective effects. Under investigation for heart failure, pulmonary fibrosis, COVID-19 sequelae, and metabolic syndrome.

Clinical Focus

ACE2/MasR Axis, Vasodilation, Anti-fibrotic, Cardioprotection

Archival Aliases

Ang(1-7), Mas Receptor Agonist, ACE2 Counter-Peptide

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: 899.0 Da | Sequence: Asp-Arg-Val-Tyr-Ile-His-Pro | ACE2 cleavage product of Ang II
Primary Pathway Cardiovascular & Anti-inflammatory
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov
[REF 3] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-04-14

Synergistic Matrix